Session » Cytokines & Cell Trafficking Poster
- 10:30AM-12:30PM
-
Abstract Number: 0879
A Novel, Oral, Allosteric Inhibitor of Tyrosine Kinase 2 (TYK2) Demonstrates In Vitro Potency, Selectivity, and In Vivo Efficacy in Mouse Models of Psoriasis
- 10:30AM-12:30PM
-
Abstract Number: 0882
Brepocitinib, a Selective TYK2/JAK1 Inhibitor Under Evaluation for the Treatment of Dermatomyositis, Reduces Inflammatory Cytokine Signaling and Interferon-induced Apoptosis in Primary Human Epidermal Keratinocytes
- 10:30AM-12:30PM
-
Abstract Number: 0881
Cytokine Profile of Newly Diagnosed Patients with Isolated Polymyalgia Rheumatica
- 10:30AM-12:30PM
-
Abstract Number: 0880
Investigating the SRPK-1-VEGF-A Alternative Splicing Pathway AsaTherapeutic Target in Arthritis
- 10:30AM-12:30PM
-
Abstract Number: 0883
The Study of 62 Circulating Soluble Factors Is Able to Predict the Lack of Response to MTX Treatment in Recently Diagnosed DMARD Naïve Rheumatoid Arthritis Smoker and Non-Smoker Patients
- 10:30AM-12:30PM
-
Abstract Number: 0878
YY1 a Potential Modulator of IL17/IL23 Axis in Psoriasis Disease
- 10:30AM-12:30PM
-
Abstract Number: 0877
Zasocitinib (TAK-279) Displays High Levels of TYK2 Inhibition and No Inhibition of JAK 1/3 Compared with Licensed TYK2 and JAK Inhibitors